RT Journal Article
SR Electronic
T1 Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21260085
DO 10.1101/2021.07.06.21260085
A1 Gaitán-Duarte, Hernando Guillermo
A1 Álvarez-Moreno, Carlos
A1 Rincón-Rodríguez, Carlos Javier
A1 Yomayusa-González, Nancy
A1 Cortés, Jorge Alberto
A1 Villar, Juan Carlos
A1 Bravo-Ojeda, Juan Sebastián
A1 García-Peña, Ángel
A1 Adarme-Jaimes, Wilson
A1 Rodríguez-Romero, Viviana Alejandra
A1 Villate-Soto, Steffany Lorena
A1 Buitrago, Giancarlo
A1 Chacón-Sarmiento, Julio
A1 Macías-Quintero, Martín
A1 Vaca, Claudia Patricia
A1 Gómez-Restrepo, Carlos
A1 Rodríguez-Malagón, Nelcy
YR 2021
UL http://medrxiv.org/content/early/2021/07/10/2021.07.06.21260085.abstract
AB BACKGROUND The effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir, and of their combined use in hospitalized patients with coronavirus disease 2019 (Covid-19) pneumonia is unclear.METHODS In each hospital, hospitalized adults with Covid-19 pneumonia, were randomly assigned, in a 1:1 ratio, to receive: a) standard of care; or b) emtricitabine/tenofovir; or c) colchicine + rosuvastatin; or d) emtricitabine/tenofovir + colchicine + rosuvastatin. The primary outcome was all-cause mortality within the first 28 days after randomization. Severe adverse events (SAE) were those with a high probability of being treatment-related.RESULTS 633 patients were randomized in 6 hospitals in Bogota, Colombia. Overall, 98% of the patients received glucocorticoids during hospitalization. The cumulative incidence of death through day 28 was 10.7% in the emtricitabine/tenofovir + colchicine + rosuvastatin arm, 14.4% in the colchicine + rosuvastatin arm, 13.8% in the emtricitabine/tenofovir arm, and 17.4% in the standard of care arm, with adjusted risk differences (aRD) against the standard treatment of -0.07 (95% confidence interval [CI], -0.17 to 0.04), aRD -0.03 (95%CI: -0.11 to 0.05) and aRD: -0.05 (95%CI: -0.15 to 0.05), respectively. Need for invasive mechanical ventilation was lower in the emtricitabine/tenofovir + colchicine + rosuvastatin arm compared to the standard treatment arm, aRD: -0.06 (95%CI: -0.11 to -0,01), but no differences were found between the other comparisons. SAE occurred in 3 patients distributed in the 3 treatment arms.CONCLUSIONS Among patients hospitalized with moderate and severe SARS Covid-19, the use of the emtricitabine/tenofovir + colchicine + rosuvastatin combination emerges as a treatment alternative.ClinicalTrials.gov number: NCT04359095Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov number: NCT04359095Funding StatementThe study was funded by the Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol and informed consent template were approved by the Universidad Nacional de Colombia Ethics Committee and by the Institutional Review Boards of the participating hospitalsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be shared upon request to the corresponding author: Hernando Gaitan-Duarte hggaitand{at}unal.edu.co